China Tongxinluo Study for Myocardial Protection in Patients With Acute Myocardial Infarction

Inclusion Criteria: 1. Age\>18 years; 2. Within 24 hours of infarctional chest pain onset; 3. ECG shows ST-segment elevation ≥0.2mV in more than 2 adjacent leads, or new left bundle branch block (LBBB); 4. Voluntary participation in the study with consent forms signed. Exclusion Criteria: 1. Critically illness due to STEMI; 2. Long-term (\>20 min) cardio-pulmonary resuscitation (CPR); 3. Suspected aortic dissection or acute pulmonary embolism; 4. Explicit mechanical complications, including interventricular septum perforation, rupture of papillary muscles and chordae tendineae, or on-going or ruptured left ventricular free walls. 5. Serious cardiogenic shock and do not responding to hypertensive agents; 6. Uncontrolled acute left heart failure or pulmonary edema; 7. Malignant arrhythmias uncontrolled by anti-arrhythmia agents; 8. Bleeding history of cerebral vessels, gastrointestinal tract, respiratory tract, urinary tract or other organs within 1 month; 9. Presence of active hemorrhage at any part of the body (including menstruation); 10. Known hemorrhagic constitution or serious hemostasis and blood coagulation disorders; 11. Current usage of anticoagulants (such as Warfarin or new anticoagulants); 12. . Serious hepatorenal dysfunction \[ATL≥5 ULN (upper limit of normal), Cr\>134μmol/L (2mg%) or eGFR\<45ml/min/1.73m2\]; 13. Serious chronic obstructive pulmonary disease (COPD) or respiratory failure; 14. . Severe infection: 15. . Very weak or frailty; 16. . Neuropsychiatric system diseases; 17. . Malignancies; 18. . Other pathophysiological conditions with expected survival time \<1 year; 19. Allergy to the ingredients of this investigational drug; 20. Women who are in pregnancy or nursery; 21. Participation in clinical study of other traditional Chinese medicine (TCM); 22. Unsuitability to participate in this study due to other diseases.